# Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment

> **NCT06592612** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 70 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Oligoprogression

## Interventions

- **RADIATION:** SBRT and second-line systemic therapy
- **DRUG:** Second-line systemic therapy

## Key facts

- **NCT ID:** NCT06592612
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06592612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06592612, "Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06592612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*